MOUNJARO® 7.5mg KwikPen®, 1 Stk.

What is MOUNJARO® 7.5mg KwikPen®

MOUNJARO® 7.5mg KwikPen® is a multi-dose, pre-filled injection device delivering 7.5 mg tirzepatide in 0.6 mL once weekly via subcutaneous injection. It is used for the treatment of adults with type 2 diabetes mellitus and as an adjunct for weight management in patients who meet clinical BMI thresholds. Each KwikPen® contains 2.4 mL of solution (total of 30 mg tirzepatide) and supplies four fixed doses. The solution is a clear, colourless to slightly yellow liquid, administered in the abdomen, thigh, or upper arm.

• Dose per injection: 7.5 mg tirzepatide in 0.6 mL

• Total pen content: 30 mg/2.4 mL (12.5 mg/mL)

• Number of doses per pen: 4

• Injection sites: Abdomen, thigh, upper arm

• Administration: Subcutaneous only

What is the Administration Protocol for MOUNJARO® 7.5mg KwikPen®

The 7.5 mg dose is commonly used as an intermediate titration step in the dosing schedule. Administration occurs once weekly, with careful timing and site rotation to optimize tolerability.

• Initiation: Start with 2.5 mg weekly for 4 weeks, then increase in 2.5 mg increments

• Titration: 7.5 mg is a transitional dose before advancing to higher levels if tolerated

• Maintenance doses: 5 mg, 10 mg, or 15 mg once weekly depending on patient needs

• Missed dose protocol:

  • If ≤4 days late: inject as soon as possible

  • If >4 days late: skip and resume on next scheduled day

• Injection technique:

  • Use a new sterile needle for each injection

  • Dial to 1 in the dose window (=0.6 mL)

  • Inject subcutaneously, hold for 5 seconds until dose window shows 0

• Rotate injection sites to minimize local irritation

What are the Indications for MOUNJARO® 7.5mg KwikPen®

This dose is indicated as part of the broader therapeutic use of tirzepatide for metabolic disorders. It serves both in glycaemic regulation and in weight management for qualifying adults.

• Indications:

  • Treatment of adults with type 2 diabetes mellitus, as monotherapy or with other antidiabetic medicines

  • Weight management in adults with BMI ≥30 kg/m²

  • Adults with BMI ≥27 to <30 kg/m² plus at least one weight-related comorbidity (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, or prediabetes)

• Contraindications:

  • Hypersensitivity to tirzepatide or excipients

• Precautions:

  • History of pancreatitis

  • Severe gastrointestinal disease (e.g., gastroparesis)

• Adverse effects:

  • Common: Nausea, diarrhoea, vomiting, abdominal pain, constipation

  • Hypoglycaemia risk increased with insulin or sulphonylureas

  • Mild to moderate injection-site reactions

  • Occasional gallbladder events

  • Rare: Acute pancreatitis, hypersensitivity

What is the composition of MOUNJARO® 7.5mg KwikPen®

The pen is formulated with tirzepatide as the active pharmaceutical ingredient, supported by excipients for stability and preservation.

• Active substance: Tirzepatide 7.5 mg/0.6 mL

• Total content per pen: 30 mg in 2.4 mL

• Concentration: 12.5 mg/mL

• Excipients: Disodium hydrogen phosphate heptahydrate, benzyl alcohol (~5.4 mg per 0.6 mL dose), glycerol, phenol, sodium chloride, sodium hydroxide, hydrochloric acid, water for injections

• Sodium content: <1 mmol sodium per dose (sodium-free)

• Appearance: Clear, colourless to slightly yellow solution

What Comes in the MOUNJARO® 7.5mg KwikPen® Package

The packaging ensures correct dosing support, though pen needles must be acquired separately.

• Presentation: Pre-filled KwikPen® with 2.4 mL (4 doses)

• Pack sizes: 1 or 3 pens per carton (availability may vary)

• Needles: Not included; must be obtained separately

• Documentation: Patient Information Leaflet (PIL) and Instructions for Use (IFU) supplied

Does MOUNJARO® 7.5mg KwikPen® cause side effects?

MOUNJARO® may produce side effects, primarily gastrointestinal in origin, which are dose-dependent and most frequent during early treatment phases.

• Very common: Nausea, diarrhoea, vomiting, abdominal pain, constipation

• Hypoglycaemia: Higher risk with concomitant insulin or sulphonylurea use

• Injection-site reactions: Reported in up to 6% of patients, mild to moderate in severity

• Gallbladder events: Reported in 1–2% of cases

• Uncommon but serious: Acute pancreatitis, hypersensitivity reactions (e.g., angioedema, anaphylaxis)

• Laboratory findings: Mild elevations in amylase and lipase

How should MOUNJARO® 7.5mg KwikPen® be stored?

Storage protocols are essential to ensure sterility, stability, and potency.

• Unopened pens: Refrigerate at 2–8 °C

• Do not freeze; discard if frozen

• After first use: May store at ≤30 °C for up to 30 days

• Discard after 30 days, regardless of remaining solution

• Needles: Remove after each injection; discard in a sharps container

• Keep out of reach of children